Per Omvik

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Björn Dahlöf, Richard B. Devereux, Sverre E. Kjeldsen et al. · The Lancet · 2002 · 5.4K citations

Hypertension, Cardiovascular Disease, Endpoint Reduction +7

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Lars Lindholm, Hans Ibsen, Björn Dahlöf et al. · The Lancet · 2002 · 1.6K citations

Hypertension, Cardiovascular Disease, Health Policy +9

Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients

Hans Ibsen, Michael Hecht Olsen, Kristian Wachtell et al. · Hypertension · 2005 · 563 citations

Cardiovascular Events, Hypertension, Urology +15

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

Aud Høieggen, Michael H. Alderman, Sverre E. Kjeldsen et al. · Kidney International · 2004 · 475 citations

Metabolic Syndrome, Urology, Serum Uric Acid +9

Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy

Sverre E. Kjeldsen, Björn Dahlöf, Richard B. Devereux et al. · JAMA · 2002 · 442 citations